SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/240196"
 

Search: onr:"swepub:oai:gup.ub.gu.se/240196" > Recombinant Human E...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Recombinant Human Erythropoietin Improves Neurological Outcomes in Very Preterm Infants

Song, J. (author)
Sun, H. Q. (author)
Xu, F. L. (author)
show more...
Kang, W. Q. (author)
Gao, L. (author)
Guo, J. J. (author)
Zhang, Y. H. (author)
Xia, L. (author)
Wang, Xiaoyang, 1965 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
Zhu, Changlian, 1964 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
show less...
 (creator_code:org_t)
2016-05-11
2016
English.
In: Annals of Neurology. - : Wiley. - 0364-5134 .- 1531-8249. ; 80:1, s. 24-34
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objective: To evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants. Methods: A total of 800 infants of <= 32-week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly assigned to receive rhEPO (500IU/kg; n=366) or placebo (n=377) intravenously within 72 hours after birth and then once every other day for 2 weeks. The primary outcome was death or moderate to severe neurological disability assessed at 18 months of corrected age. Results: Death and moderate/severe neurological disability occurred in 91 of 338 very preterm infants (26.9%) in the placebo group and in 43 of 330 very preterm infants (13.0%) in the rhEPO treatment group (relative risk [RR]=0.40, 95% confidence interval [CI]=0.27-0.59, p < 0.001) at 18 months of corrected age. The rate of moderate/severe neurological disability in the rhEPO group (22 of 309, 7.1%) was significantly lower compared to the placebo group (57 of 304, 18.8%; RR=0.32, 95% CI=0.19-0.55, p < 0.001), and no excess adverse events were observed. Interpretation: Repeated low-dose rhEPO treatment reduced the risk of long-term neurological disability in very preterm infants with no obvious adverse effects.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

birth-weight infants
high-dose erythropoietin
hypoxia-ischemia
white-matter
brain-injury
retinopathy
neuroprotection
safety
trial
born
Neurosciences & Neurology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view